Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    October 2018
  1. AMSCHLER K, Beyazpinar I, Erpenbeck L, Kruss S, et al
    Morphological Plasticity of Human Melanoma Cells is Determined by Nanoscopic Patterns of E- and N-Cadherin Interactions.
    J Invest Dermatol. 2018 Oct 27. pii: S0022-202X(18)32710.
    PubMed     Text format     Abstract available


  2. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Association between phenotypic characteristics and melanoma in a large prospective cohort study.
    J Invest Dermatol. 2018 Oct 24. pii: S0022-202X(18)32692.
    PubMed     Text format     Abstract available


    August 2018
  3. GILES KM, Rosenbaum BE, Berger M, Izsak A, et al
    Revisiting the clinical and biologic relevance of partial PTEN loss in melanoma.
    J Invest Dermatol. 2018 Aug 24. pii: S0022-202X(18)32503.
    PubMed     Text format     Abstract available


  4. PAMPENA R, Pellacani G, Longo C
    Nevus-Associated Melanoma: Patient Phenotype and Potential Biological Implications.
    J Invest Dermatol. 2018;138:1696-1698.
    PubMed     Text format     Abstract available


  5. SAHOO A, Sahoo SK, Joshi P, Lee B, et al
    MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma.
    J Invest Dermatol. 2018 Aug 1. pii: S0022-202X(18)32458.
    PubMed     Text format     Abstract available


    July 2018
  6. RAMSPOTT JP, Bekkat F, Bod L, Favier M, et al
    Emerging role of IL4-induced gene 1 as a prognostic biomarker affecting the local T cell response in human cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 23. pii: S0022-202X(18)32301.
    PubMed     Text format     Abstract available


  7. NOSRATI A, Yu WY, McGuire J, Griffin A, et al
    Outcomes and risk factors in patients with multiple primary melanomas.
    J Invest Dermatol. 2018 Jul 19. pii: S0022-202X(18)32359.
    PubMed     Text format     Abstract available


  8. FORSTHUBER A, Lipp K, Andersen L, Ebersberger S, et al
    CXCL5 as regulator of neutrophil function in cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 13. pii: S0022-202X(18)32353.
    PubMed     Text format     Abstract available


  9. TAKAISHI M, Sano S
    Transdifferentiation of melanoma cells by the reprogramming factors attenuates malignant nature in vitro and in vivo.
    J Invest Dermatol. 2018 Jul 7. pii: S0022-202X(18)32303.
    PubMed     Text format    


    June 2018
  10. CUST AE, Drummond M, Kanetsky PA, Goldstein AM, et al
    Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies.
    J Invest Dermatol. 2018 Jun 8. pii: S0022-202X(18)32046.
    PubMed     Text format     Abstract available


    May 2018
  11. RAMANI V, Teshima T, Tamura K, Chung JS, et al
    Melanoma-derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-lymphocytes from the Pre-metastatic Niches.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31987.
    PubMed     Text format     Abstract available


  12. NAWAZ A, Wong TW
    Chitosan-carboxymethyl-5-fluorouracil-folate conjugate particles: Microwave modulated uptake by skin and melanoma cells.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31985.
    PubMed     Text format     Abstract available


  13. THOMAS NE, Edmiston SN, Orlow I, Kanetsky PA, et al
    Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962.
    PubMed     Text format     Abstract available


  14. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Physician skin checks before the diagnosis of melanoma correlate with tumor characteristics.
    J Invest Dermatol. 2018 May 4. pii: S0022-202X(18)31952.
    PubMed     Text format    


    April 2018
  15. NORDLINGER A, Dror S, Elkahloun A, Del Rio J, et al
    Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
    J Invest Dermatol. 2018 Apr 18. pii: S0022-202X(18)31873.
    PubMed     Text format     Abstract available


    March 2018
  16. YANG Y, Guo W, Ma J, Xu P, et al
    Down-regulated TRPV1 expression contributes to melanoma growth via calcineurin-ATF3-p53 pathway.
    J Invest Dermatol. 2018 Mar 23. pii: S0022-202X(18)31748.
    PubMed     Text format     Abstract available


  17. PANDEYA N, Kvaskoff M, Olsen CM, Green AC, et al
    Factors related to nevus-associated cutaneous melanoma: a case-case study.
    J Invest Dermatol. 2018 Mar 7. pii: S0022-202X(18)30204.
    PubMed     Text format     Abstract available


    February 2018
  18. SOLER-CARDONA A, Forsthuber A, Lipp K, Ebersberger S, et al
    CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis.
    J Invest Dermatol. 2018 Feb 20. pii: S0022-202X(18)30125.
    PubMed     Text format     Abstract available


  19. LIN J, Zhang D, Fan Y, Chao Y, et al
    Regulation of cancer stem cell self-renewal by HOXB9 antagonizes ER stress-induced melanoma cell apoptosis via the miR-765-FOXA2 axis.
    J Invest Dermatol. 2018 Feb 3. pii: S0022-202X(18)30105.
    PubMed     Text format     Abstract available


  20. TUCKER MA, Elder DE, Curry M, Fraser MC, et al
    Risks of melanoma and other cancers in melanoma-prone families over four decades.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30102.
    PubMed     Text format     Abstract available


  21. ELIADES P, Abraham BJ, Ji Z, Miller DM, et al
    High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30106.
    PubMed     Text format     Abstract available


  22. CARRERA C, Puig-Butille JA
    Clinical, Epidemiological, and Molecular Heterogeneity in Acral Melanoma.
    J Invest Dermatol. 2018;138:254-255.
    PubMed     Text format     Abstract available


    January 2018
  23. FAIAO-FLORES F, Smalley KSM
    Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.
    J Invest Dermatol. 2018;138:10-13.
    PubMed     Text format     Abstract available


    December 2017
  24. OGAWA H, Luxardi G, Kirane A, Kulkarni R, et al
    T cells dominate the local immune response induced by intralesional IL-2 in combination with imiquimod and retinoid for in-transit metastatic melanoma.
    J Invest Dermatol. 2017 Dec 29. pii: S0022-202X(17)33369.
    PubMed     Text format    


  25. CONIC RZ, Arbesman J
    Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage.
    J Invest Dermatol. 2017 Dec 5. pii: S0022-202X(17)33236.
    PubMed     Text format    


  26. KASUMOVA GG, Haynes AB, Boland GM
    Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application.
    J Invest Dermatol. 2017;137:2466-2468.
    PubMed     Text format     Abstract available


  27. CHHABRA G, Wojdyla L, Frakes M, Schrank Z, et al
    Mechanism of action of G-quadruplex forming oligonucleotide homologous to the telomere overhang in melanoma.
    J Invest Dermatol. 2017 Dec 1. pii: S0022-202X(17)33229.
    PubMed     Text format     Abstract available


    November 2017
  28. MOON KR, Choi YD, Kim JM, Jin S, et al
    Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    J Invest Dermatol. 2017 Nov 27. pii: S0022-202X(17)33225.
    PubMed     Text format     Abstract available


  29. LIU SM, Lin CH, Lu J, Lin IY, et al
    miR-596 modulates melanoma growth by regulating cell survival and death.
    J Invest Dermatol. 2017 Nov 25. pii: S0022-202X(17)33172.
    PubMed     Text format     Abstract available


  30. WANG YF, Liu F, Sherwin S, Farrelly M, et al
    Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells.
    J Invest Dermatol. 2017 Nov 22. pii: S0022-202X(17)33164.
    PubMed     Text format     Abstract available


  31. LOHCHAROENKAL W, Das Mahapatra K, Pasquali L, Crudden C, et al
    Genome-wide screen for microRNAs reveals a role for miR-203 in melanoma metastasis.
    J Invest Dermatol. 2017 Nov 2. pii: S0022-202X(17)33137.
    PubMed     Text format     Abstract available


    October 2017
  32. RUBEL F, Kern JS, Technau-Hafsi K, Uhrich S, et al
    Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with Breslow thickness and is of significant prognostic value for progression-free survival.
    J Invest Dermatol. 2017 Oct 17. pii: S0022-202X(17)33059.
    PubMed     Text format     Abstract available


    September 2017
  33. HEPPT MV, Wang JX, Hristova DM, Wei Z, et al
    MSX1-induced neural crest-like reprogramming promotes melanoma progression.
    J Invest Dermatol. 2017 Sep 16. pii: S0022-202X(17)32807.
    PubMed     Text format     Abstract available


  34. HAO J, Xu H, Luo M, Yu W, et al
    The tumor-promoting role of TRIP4 in melanoma progression and its involvement in response to BRAF-targeted therapy.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32937.
    PubMed     Text format     Abstract available


  35. YU B, Alboslemy T, Safadi F, Kim MH, et al
    Glycoprotein non-melanoma clone B regulates the crosstalk between macrophages and mesenchymal stem cells towards wound repair.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32934.
    PubMed     Text format     Abstract available


  36. HAUGH AM, Zhang B, Quan VL, Garfield EM, et al
    Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
    J Invest Dermatol. 2017 Sep 1. pii: S0022-202X(17)32917.
    PubMed     Text format     Abstract available


    August 2017
  37. DONOVAN P, Dubey OA, Kallioinen S, Rogers KW, et al
    Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion.
    J Invest Dermatol. 2017 Aug 24. pii: S0022-202X(17)32820.
    PubMed     Text format     Abstract available


  38. DELYON J, Chevret S, Jouary T, Dalac S, et al
    STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.
    J Invest Dermatol. 2017 Aug 23. pii: S0022-202X(17)32802.
    PubMed     Text format     Abstract available


  39. THOMAS NE, Edmiston SN, Kanetsky PA, Busam KJ, et al
    Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32791.
    PubMed     Text format     Abstract available


  40. VON SCHUCKMANN LA, Smith D, Hughes MCB, Malt M, et al
    Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32797.
    PubMed     Text format     Abstract available


  41. TAYLOR NJ, Mitra N, Goldstein AM, Tucker MA, et al
    Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
    J Invest Dermatol. 2017 Aug 19. pii: S0022-202X(17)32759.
    PubMed     Text format     Abstract available


    July 2017
  42. DAI W, Xu X, Li S, Ma J, et al
    SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells.
    J Invest Dermatol. 2017 Jul 28. pii: S0022-202X(17)32684.
    PubMed     Text format     Abstract available


  43. ISHIDA Y, Otsuka A, Tanaka H, Levesque MP, et al
    HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31863.
    PubMed     Text format    


  44. CLARKE CA, McKinley M, Hurley S, Haile RW, et al
    Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998-2012.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31867.
    PubMed     Text format     Abstract available


  45. GASSENMAIER M, Eigentler TK, Keim U, Goebeler M, et al
    Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31871.
    PubMed     Text format     Abstract available


    June 2017
  46. VAN TUYN J, Jaber-Hijazi F, MacKenzie D, Cole JJ, et al
    Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function.
    J Invest Dermatol. 2017 Jun 21. pii: S0022-202X(17)31662.
    PubMed     Text format     Abstract available


  47. ASGARI MM, Chien AJ, Tsai AL, Fireman B, et al
    Association between lithium use and melanoma risk and mortality: A population-based study.
    J Invest Dermatol. 2017 Jun 16. pii: S0022-202X(17)31644.
    PubMed     Text format     Abstract available


  48. THEODOSAKIS N, Micevic G, Langdon CG, Ventura A, et al
    p90RSK blockade inhibits dual BRAF and MEK inhibitor-resistant melanoma by targeting protein synthesis.
    J Invest Dermatol. 2017 Jun 6. pii: S0022-202X(17)31603.
    PubMed     Text format     Abstract available


    May 2017
  49. BUSTOS MA, Ono S, Marzese DM, Oyama T, et al
    MiR-200a Regulates CDK4/6 Inhibitor Effect by targeting CDK6 in Metastatic Melanoma.
    J Invest Dermatol. 2017 May 16. pii: S0022-202X(17)31528.
    PubMed     Text format     Abstract available


  50. SHI Q, Liu H, Han P, Li C, et al
    Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.
    J Invest Dermatol. 2017 May 9. pii: S0022-202X(17)31489.
    PubMed     Text format     Abstract available


  51. LEITER U, Keim U, Eigentler T, Katalinic A, et al
    Incidence, Mortality and Trends of Non-Melanoma Skin Cancer in Germany.
    J Invest Dermatol. 2017 May 6. pii: S0022-202X(17)31482.
    PubMed     Text format     Abstract available


  52. BAUER J
    The Molecular Revolution in Cutaneous Biology: Era of Cytogenetics and Copy Number Analysis.
    J Invest Dermatol. 2017;137:e57-e59.
    PubMed     Text format     Abstract available


    April 2017
  53. FANG S, Wang Y, Dang Y, Gagel A, et al
    Association between body mass index, C-reactive protein levels, and melanoma patient outcomes.
    J Invest Dermatol. 2017 Apr 22. pii: S0022-202X(17)31423.
    PubMed     Text format    


  54. KIM SH, Li M, Trousil S, Zhang Y, et al
    Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma.
    J Invest Dermatol. 2017 Apr 19. pii: S0022-202X(17)31420.
    PubMed     Text format     Abstract available


  55. SEO EY, Jin SP, Sohn KC, Park CH, et al
    UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes.
    J Invest Dermatol. 2017 Apr 6. pii: S0022-202X(17)31396.
    PubMed     Text format     Abstract available


  56. SFECCI A, Dupuy A, Dinulescu M, Droitcourt C, et al
    Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    J Invest Dermatol. 2017;137:805-809.
    PubMed     Text format     Abstract available


    February 2017
  57. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Text format     Abstract available


  58. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.
    PubMed     Text format    


    January 2017
  59. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Text format     Abstract available


  60. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.
    PubMed     Text format    


    December 2016
  61. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Text format     Abstract available


  62. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Text format     Abstract available


    November 2016
  63. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Text format     Abstract available


  64. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Text format     Abstract available


    October 2016
  65. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.
    PubMed     Text format    


  66. ELIADES P, Tsao H
    New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship.
    J Invest Dermatol. 2016;136:1933-5.
    PubMed     Text format     Abstract available


    September 2016
  67. VIARISIO D, Muller-Decker K, Hassel JC, Alvarez JC, et al
    The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice.
    J Invest Dermatol. 2016 Sep 17. pii: S0022-202X(16)32449.
    PubMed     Text format    


  68. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Text format     Abstract available


    July 2016
  69. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Text format     Abstract available


    May 2016
  70. POSCH C, Sanlorenzo M, Vujic I, Oses-Prieto JA, et al
    Phospho-proteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2alpha kinase levels in NRAS(Q61) mutant cells.
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31261.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: